Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Melanoma Frontier Opens To Bristol's Opdivo And Novartis/Glaxo's BRAF/MEK Combo

Executive Summary

Bristol's Opdivo and Novartis/GlaxoSmithKline's Tafinlar/Mekinist combo both performed well in early, post-surgical treatment of advanced melanoma in trials reported at ESMO, promising yet another revolution in the standard of care, but leaving Roche's Zelboraf/Cotellic in the dust.

Advertisement

Related Content

Will Keytruda Price Differential Really Count In India?
New Keytruda Approval Rekindles An Old Debate
New PD-1 Immunotherapy Combinations Push The Envelope In Melanoma
Genentech Catching Up In Melanoma With Cotellic Approval
Melanoma Approvals Break New Ground In Immunotherapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel